Pfizer, Inc.
Loading chart...
| ITEM 1. | BUSINESS |
ABOUT PFIZER
Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of
| Pfizer Inc. | 2025 Form 10-K | 3 |
biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The Company was incorporated under the laws of the State of Delaware on June 2, 1942.
Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients through improved treatment of diseases and improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room visits or hospitalizations. We seek to enhance the value of our medicines and vaccines and actively engage in dialogues about how we can best work with patients, physicians and payors to prevent and treat disease and improve outcomes. We seek to maximize patient access and evaluate our pricing arrangements and contracting methods with payors to minimize adverse impact on our revenues within the current legal and pricing structures.
We are committed to fulfilling our purpose: Breakthroughs that change patients’ lives. Our purpose fuels everything we do and reflects both our passion for science and our commitment to patients. As a science-driven global biopharmaceutical company, we remain focused on advancing our product pipeline, supporting our marketed brands and deploying capital responsibly, with a focus on initiatives that can help contribute to our long-term revenue and future growth.
Our 2026 key priorities are:
1.Maximize value of key transactions
2.Deliver on critical R&D milestones
3.Invest to maximize post-2028 growth
4.Scale AI across our business.
We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our business strategy.
For a discussion of our strategy and our business development initiatives, including our acquisitions of Metsera in November 2025 and Seagen in December 2023 and our in-licensing agreements with YaoPharma and 3SBio entered into in 2025 in the obesity and cardiometabolic diseases and oncology therapeutic areas, see the Overview of Our Performance, Operating Environment, Strategy and Outlook section within MD&A and Note 2. In addition, we are scaling AI across R&D, manufacturing, commercial and patient engagement to improve productivity and accelerate innovation.
COMMERCIAL OPERATIONS
We manage our commercial operations through a global structure consisting of three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma, our innovative science-based biopharmaceutical business, is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Pfizer Ignite is an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with our R&D focus areas. In 2025, Pfizer made the decision to discontinue Pfizer Ignite and we are winding down this business while collaborating closely with our Ignite partners to ensure continuity and the successful transition of work. Biopharma is the only reportable segment.
Within our Biopharma reportable segment, our commercial divisions market, sell and distribute our products, and global operating functions are responsible for the research, development, manufacturing and supply of our products. The commercial structure within our Biopharma reportable segment in 2025 was composed of the Pfizer U.S. Commercial Division, which focused on the commercialization of Pfizer’s entire product portfolio in the U.S., and the Pfizer International Commercial Division, which focused on the commercialization of Pfizer’s entire product portfolio in all international markets.
As part of our continued focus on commercial execution, at the beginning of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars from the Specialty Care and Oncology product portfolios to a new Global Hospital and Biosimilars organization within our Biopharma reportable segment. Effective January 1, 2026, the commercial structure within our Biopharma reportable segment is as follows:
Division | Description | ||||
Pfizer U.S. Commercial | Includes the U.S. commercial organization covering Pfizer’s entire product portfolio except for the Global Hospital and Biosimilars organization, as well as the Global Access & Value, Global Chief Marketing Office and Primary Care and Specialty Care U.S. Medical Affairs organizations. | ||||
Pfizer International Commercial | Includes the ex-U.S. commercial and medical affairs organizations covering Pfizer’s entire product portfolio in all international markets except for the Global Hospital and Biosimilars organization in certain international markets. | ||||
Global Hospital and Biosimilars | Includes the commercial organization covering Pfizer’s product portfolio of off-patent branded and generic sterile injectables and biosimilars except in China, Hong Kong and certain other international markets. |
Customer groups and select products within the Biopharma product portfolio in 2026 include:
•Primary Care:
◦Internal medicine product portfolio including in cardiovascular metabolic diseases – select products include: Eliquis, as well as other brands that have experienced patent-based expirations or loss of regulatory exclusivity.
◦Migraine product portfolio: Nurtec ODT/Vydura and Zavzpret.
◦Vaccines product portfolio across all ages – select products include: the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba.
◦Treatment for COVID-19: Paxlovid.
| Pfizer Inc. | 2025 Form 10-K | 4 |
•Specialty Care:
◦Inflammation & immunology product portfolio – select products include: Xeljanz, Enbrel (outside the U.S. and Canada), Cibinqo, Litfulo, Eucrisa and Velsipity.
◦Rare disease product portfolio for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia and endocrine diseases – select products include: the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla and Hympavzi.
◦Certain anti-infective and immunoglobulin medicines – select products include: Zavicefta (outside the U.S. and Canada), Octagam and Panzyga.
•Oncology:
◦Innovative oncology product portfolio of ADCs, small molecules, bispecifics and other immunotherapies that treat a wide range of cancers including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer – select products include: Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna.
•Hospital and Biosimilars:
◦Product portfolio of off-patent branded and generic sterile injectables, oncology biosimilars and biosimilars for chronic immune and inflammatory diseases – select products include: Biosimilars – Inflectra, Oncology biosimilars such as Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and Sterile Injectables – Sulperazon (outside the U.S. and Canada), Atgam, Fragmin, Solu Medrol, Solu Cortef and Bicillin.
For additional information on our operating segments and products, including product revenues, see Note 17, and for additional information on the key operational revenue drivers of our business, see the Analysis of the Consolidated Statements of Operations section within MD&A. For a discussion of the risks associated with our dependence on certain of our major products, see the Item 1A. Risk Factors—Concentration section.
RESEARCH AND DEVELOPMENT
R&D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients’ lives as we work to translate advanced science and technologies into the medicines and vaccines that may be the most impactful for patients. In addition to discovering and developing new products, our R&D efforts seek to add value to our existing products by improving their safety, efficacy and ease of dosing and by discovering potential new indications.
Our R&D Priorities and Strategy. Our R&D priorities include:
•delivering a pipeline of highly differentiated medicines and vaccines where we have a unique opportunity to bring the most important new therapies to patients in need;
•advancing our capabilities that can position us for long-term R&D leadership; and
•
Loading financial statements...
Financial statements
data from SEC XBRL filings. Values are as-reported; restatements supersede originals. Values reported in .
| Line item |
|---|
| Period ending |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
OPERATIONS
GENERAL
The following MD&A is intended to assist the reader in understanding our financial condition and results of operations, including an evaluation of the amounts and certainty of cash flows from operations and from outside sources, and is provided as a supplement to and should be read in conjunction with the condensed consolidated financial statements and related notes in Item 1. Financial Statements in this Form 10-Q.
References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and because they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.
OVERVIEW OF OUR PERFORMANCE, OPERATING AND GLOBAL ECONOMIC ENVIRONMENT
Our Business––Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide.
Segments––Beginning in the first quarter of 2026, we manage our commercial operations through a global structure consisting of two operating segments: Biopharma and PC1. Biopharma is the only reportable segment. See Note 13A.
For additional information about our business, strategy and operating environment, see the Item 1. Business section and the Overview of Our Performance, Operating Environment, Strategy and Outlook section within MD&A of our 2025 Form 10-K.
Restructuring Programs
Realigning Our Cost Base Program––In the third quarter of 2026, we announced $1.0 billion of additional anticipated net cost savings associated with this program driven by further productivity enhancements from technology and simplification efforts across our commercial, R&D and enabling functions. These additional net savings are expected to further reduce costs in SI&A and be realized from 2027 through 2029. We expect one-time costs to achieve the additional savings to be incurred through 2029 and to total approximately $2.0 billion.
Manufacturing Optimization Program––In the third quarter of 2026, we announced the next phase of our multi-year program designed to reduce our cost of goods sold focused on network structure changes, product portfolio enhancements and additional operational efficiencies which is expected to deliver additional anticipated savings of approximately $1.5 billion from 2027 through 2029. The one-time costs to achieve the savings associated with this phase of the program are expected to be approximately $4.0 billion, with approximately 60% representing non-cash expenditures. The costs to achieve these savings are expected to be incurred through 2029.
For a description of anticipated savings related to these programs, see the Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives section within MD&A and Note 3 for the anticipated and actual costs of these programs.
Our Business Development Initiatives––We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. For a description of the more significant recent transactions through February 26, 2026, the filing date of our 2025 Form 10-K, see Note 2 in our 2025 Form 10-K. In addition, for a discussion of our acquisition of Metsera in November 2025 and other recent business development initiatives, see Note 2.
Our Third Quarter and First Nine Months of 2026 Performance
Total Revenues––Total revenues decreased $71 million in the third quarter of 2026 to $16.6 billion from $16.7 billion in the third quarter of 2025, or relatively flat on a percentage basis, reflecting an operational decrease of $57 million, as well as an unfavorable impact of foreign exchange of $15 million. The operational decrease was driven by a decline in revenues from COVID-19 products, the Prevnar family, and several other products across categories, largely offset by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Nurtec ODT/Vydura, Lorbrena and several other products across categories. Excluding contributions from Comirnaty and Paxlovid, Total revenues increased 7% operationally.
Total revenues increased $1.0 billion, or 2%, in the first nine months of 2026 to $46.1 billion from $45.0 billion in the first nine months of 2025, reflecting an operational increase of $412 million, or 1%, as well as a favorable impact of foreign exchange of $634 million, or 1%. The operational increase was driven by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Nurtec ODT/Vydura, Lorbrena, Oncology biosimilars and several other products across categories, partially offset by a decline
34
in revenues from COVID-19 products, the Prevnar family and several other products across categories. Excluding contributions from Comirnaty and Paxlovid, Total revenues increased 7% operationally.
See the Total Revenues by Geography and Total Revenues––Selected Product Discussion sections within MD&A for more information, including a discussion of key drivers of our revenue performance for certain products, and Note 13C for additional information on our operating segments and products, including product revenues.
Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income–– The increase in Income from continuing operations before provision/(benefit) for taxes on income of $51 million, to $3.4 billion in the third quarter of 2026 from $3.3 billion in the third quarter of 2025, was primarily due to (i) decreases in Acquired in-process research and development expenses and Cost of sales, (ii) the non-recurrence of an intangible asset impairment charge recorded in the third quarter of 2025, and (iii) lower charges for certain legal matters (both (ii) and (iii) recorded in Other (income)/deductions––net), partially offset by (iv) increases in Restructuring charges and certain acquisition-related costs and Research and development expenses, (v) net losses on equity securities in the third quarter of 2026 versus net gains on equity securities in the third quarter of 2025, and (vi) increases in the fair value of our contingent consideration liabilities (both (v) and (vi) recorded in Other (income)/deductions––net).
The decrease in Income from continuing operations before provision/(benefit) for taxes on income of $3.3 billion, to $5.9 billion in the first nine months of 2026 from $9.2 billion in the first nine months of 2025, was primarily due to (i) charges for intangible asset impairments and certain legal matters, and increases in the fair value of our contingent consideration liabilities (all recorded in Other (income)/deductions––net), and (ii) increases in Research and development expenses, Cost of sales and Restructuring charges and certain acquisition-related costs, partially offset by (iii) a net gain in 2026 from the sale of our previous investment in ViiV (recorded in Other (income)/deductions––net), (iv) higher revenues, and (v) a decrease in Acquired in-process research and development expenses.
See the Analysis of the Condensed Consolidated Statements of Operations section within MD&A and Notes 3 and 4. For information on our tax provision and effective tax rate, see the Provision/(Benefit) for Taxes on Income section within MD&A and Note 5.
Our Operating Environment––We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below. See also the Item 1. Business––Government Regulation and Price Constraints and Item 1A. Risk Factors sections, and the Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment section of the MD&A of our 2025 Form 10-K.
Intellectual Property Rights and Collaboration/Licensing Rights––The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments, and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. We anticipate a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years. In 2026, we expect an unfavorable revenue impact from patent-based or regulatory exclusivity expiries of approximately $1.1 billion.
For additional information on patent rights we consider most significant to our business as a whole, including U.S., major Europe and Japan basic product patent expiration years, see the Item 1. Business––Patents and Other Intellectual Property Rights section of our 2025 Form 10-K. For a discussion of recent developments with respect to patent litigation involving certain of our products, see Notes 12A1 and 12A5.
Regulatory Environment/Pricing and Access––Government and Other Payor Group Pressures––Pricing and access pressures from governments globally, as well as private third-party payors in the U.S., continue to impact our global operations. With respect to the U.S., we expect to see continued focus by the U.S. government and states on regulating drug pricing and access to medicine, including but not limited to, international reference pricing, including Most-Favored-Nation (MFN) drug pricing. We continue to monitor and evaluate the implementation of the IRA, including the Medicare Drug Price Negotiation Program (MDPNP) and its government-set Maximum Fair Price (MFP) which became effective for Eliquis on January 1, 2026. Negotiated prices for Ibrance and Xtandi are effective in 2027. While Xeljanz remains a selected drug through 2028, the Centers for Medicare and Medicaid Services has determined that bona fide marketing of a generic version of Xeljanz exists. Accordingly, no MFP for Xeljanz will be finalized or take effect. The IRA also made significant changes to the Medicare Part D benefit design (IRA Medicare Part D Redesign), which took effect beginning in 2025. We do not expect a material, incremental impact from the IRA Medicare Part D Redesign in 2026 versus the baseline set in 2025. In addition, changes to the Medicaid Drug Rebate Program or the 340B Program, including legal or legislative developments at the federal or state level with respect to the 340B Program, could have a material impact on our business. The Department of Health and Human Services (HHS) has announced a 340B pilot program, expected to begin in January 2027, that is expected to include Eliquis, Ibrance and Xtandi. The 340B pilot program is subject to ongoing litigation. We are evaluating the potential impact. See the Item 1. Business––Pricing Pressures and Managed Care Organizations and ––Government Regulation and Price Constraints
35
and the Item 1A. Risk Factors––Pricing and Reimbursement sections, and the Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment section of the MD&A of our 2025 Form 10-K and The Global Economic Environment––Global Trade Environment section below.
Policy/Regulatory Environment––New, proposed and potential policy, regulatory or other changes from the U.S. Presidential administration, Congress and states, including, among others, increased, decreased, withdrawn or new regulatory requirements, including changes in requirements for licensure, changes, delays or failure to receive recommendations, reimbursement and regulatory approvals and coverage for our vaccines and medicines, as well as potential impacts on our activities in markets outside of the U.S., could have a material adverse effect on our business, earnings, cash flows, liquidity and financial guidance.
Product Supply––We periodically encounter supply delays, disruptions and shortages, including due to voluntary product recalls and natural or man-made disasters.
We have not experienced a significant disruption of our supply chain in the first nine months of 2026 or through the date of filing of this Form 10-Q, and substantially all of our manufacturing sites globally have continued to operate at or near normal levels. We continue to monitor potential supply chain impacts from geopolitical and trade developments. We do not currently anticipate the availability of raw materials to have a significant impact on our operations in 2026, but are monitoring potential supply chain disruptions as a result of ongoing geopolitical and trade negotiations, which could, among other things, impact costs. For information on risks related to product manufacturing, see the Item 1A. Risk Factors––Product Manufacturing, Sales and Marketing Risks section of our 2025 Form 10-K.
The Global Economic Environment––In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to economic cycles as well as broader geopolitical and regulatory developments. See the Item 1A. Risk Factors—Global Operations section of our 2025 Form 10-K, as well as the Overview of Our Performance, Operating Environment, Strategy and Outlook––The Global Economic Environment section of the MD&A of our 2025 Form 10-K.
Global Trade Environment––Issued or future executive orders or other new or changes in laws, regulations or policies regarding tariffs or other trade or foreign policy, could have a material adverse effect on our business, earnings, cash flow, liquidity and financial guidance. The regulatory landscape continues to evolve, and on April 2, 2026, the U.S. Government announced Section 232 tariffs on imported patented pharmaceuticals and their ingredients, up to a 100% duty to address national security concerns regarding supply chain reliance (the April 2, 2026 Section 232 Executive Order). These measures, featuring exemptions for commitments to onshore and invest in U.S. manufacturing, became effective for Pfizer on July 31, 2026. We have reached final binding agreements with the U.S. Government, ratifying the arrangements first announced in September 2025. Under these agreements, we have voluntarily committed to implement measures designed to make certain drug prices for U.S. patients more comparable to those in other developed countries, allow U.S. patients to purchase certain medicines at significant discounts to current retail prices and further invest in our U.S. manufacturing. Pursuant to the agreements, the applicable tariff rate under the April 2, 2026 Section 232 Executive Order for Pfizer products will be zero until January 20, 2029. We will continue to monitor developments and any potential impacts on our future financial results and business. However, there can be no assurance that the U.S. Government will not modify, or adopt new tariff or trade measures that could affect our products. For additional information on risks related to our global operations and changes in laws, see the Item 1A. Risk Factors—Global Operations and ––Changes in Laws and Accounting Standards sections of our 2025 Form 10-K.
SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS
For a description of our significant accounting policies, see Note 1 in our 2025 Form 10-K. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (Note 1D); Fair Value (Note 1E); Revenues (Note 1G); Long-Lived Assets (Note 1M); Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Note 1N); Income Taxes (Note 1Q); Pension and Postretirement Benefit Plans (Note 1R); and Legal and Environmental Contingencies (Note 1S).
For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions section within MD&A of our 2025 Form 10-K. See also Note 1C in our 2025 Form 10-K for a discussion about the risks associated with estimates and assumptions.
36
ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Total Revenues by Geography
The following presents worldwide Total revenues by geography: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | U.S. | International | World-wide | U.S. | Inter-national | |||||||||||||||||||||||||||||||||||||||||||||||||||
| (MILLIONS) | Sept. 27, 2026 | Sept. 28, 2025 | Sept. 27, 2026 | Sept. 28, 2025 | Sept. 27, 2026 | Sept. 28, 2025 | % Change | |||||||||||||||||||||||||||||||||||||||||||||||||
| Operating segments: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Biopharma | $ | 16,283 | $ | 16,310 | $ | 10,546 | $ | 10,599 | $ | 5,736 | $ | 5,711 | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Pfizer CentreOne(a) | 300 | 344 | 56 | 92 | 244 | 253 | (13) | (39) | (3) | |||||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 16,583 | $ | 16,654 | $ | 10,602 | $ | 10,691 | $ | 5,981 | $ | 5,963 | — | (1) | — | |||||||||||||||||||||||||||||||||||||||||
| Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | U.S. | International | World-wide | U.S. | Inter-national | |||||||||||||||||||||||||||||||||||||||||||||||||||
| (MILLIONS) | Sept. 27, 2026 | Sept. 28, 2025 | Sept. 27, 2026 | Sept. 28, 2025 | Sept. 27, 2026 | Sept. 28, 2025 | % Change | |||||||||||||||||||||||||||||||||||||||||||||||||
| Operating segments: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Biopharma | $ | 45,105 | $ | 44,056 | $ | 27,963 | $ | 27,677 | $ | 17,142 | $ | 16,379 | 2 | 1 | 5 | |||||||||||||||||||||||||||||||||||||||||
Pfizer CentreOne(a) | 962 | 966 | 228 | 282 | 735 | 684 | — | (19) | 7 | |||||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 46,067 | $ | 45,022 | $ | 28,191 | $ | 27,959 | $ | 17,877 | $ | 17,063 | 2 | 1 | 5 | |||||||||||||||||||||||||||||||||||||||||
(a)Includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in all periods presented. We reclassified prior period amounts to conform to the current period presentation.
Product Revenue Deductions––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these product revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.
The following presents information about product revenue deductions: | ||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (MILLIONS) | September 27, 2026 | September 28, 2025 | September 27, 2026 | September 28, 2025 | ||||||||||||||||||||||
Medicare rebates | $ | 1,008 | $ | 1,188 | $ | 2,972 | $ | 3,359 | ||||||||||||||||||
| Medicaid and related state program rebates | 371 | 522 | 1,164 | 1,309 | ||||||||||||||||||||||
| Performance-based contract rebates | 1,730 | 1,948 | 5,140 | 5,222 | ||||||||||||||||||||||
| Chargebacks | 4,533 | 4,125 | 11,315 | 10,268 | ||||||||||||||||||||||
| Sales allowances | 1,837 | 1,851 | 5,250 | 5,406 | ||||||||||||||||||||||
Sales returns and cash discounts | 583 | 517 | 1,502 | 1,156 | ||||||||||||||||||||||
| Total | $ | 10,063 | $ | 10,151 | $ | 27,343 | $ | 26,720 | ||||||||||||||||||
Product revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.
For information on our accruals for product revenue deductions, including the balance sheet classification of these accruals, see Note 1B.
Total Revenues––Selected Product Discussion
Biopharma
| (MILLIONS) | Revenue | % Change | ||||||||||||||||||||||||||||||||||||||||||||||||
| Product | Period | Global Revenues | Region | Sept. 27, 2026 | Sept. 28, 2025 | Total | Oper. | Operational Results Commentary | ||||||||||||||||||||||||||||||||||||||||||
| Eliquis | QTD | $2,523 Up 25% (operationally) | U.S. | $ | 1,808 | $ | 1,292 | 40 | QTD and YTD growth primarily driven by higher net price in the U.S. primarily due to pricing dynamics, including lower rebates and channel mix favorability, as well as higher demand globally, partially offset by declines due to generic entry and price erosion in certain international markets. | |||||||||||||||||||||||||||||||||||||||||
| Int’l. | 715 | 723 | (1) | — | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 2,523 | $ | 2,015 | 25 | 25 | ||||||||||||||||||||||||||||||||||||||||||||
| YTD | $7,114 Up 18% (operationally) | U.S. | $ | 4,895 | $ | 3,913 | 25 | |||||||||||||||||||||||||||||||||||||||||||
| Int’l. | 2,219 | 2,028 | 9 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 7,114 | $ | 5,941 | 20 | 18 | ||||||||||||||||||||||||||||||||||||||||||||
37
| (MILLIONS) | Revenue | % Change | ||||||||||||||||||||||||||||||||||||||||||||||||
| Product | Period | Global Revenues | Region | Sept. 27, 2026 | Sept. 28, 2025 | Total | Oper. | Operational Results Commentary | ||||||||||||||||||||||||||||||||||||||||||
| Vyndaqel family | QTD | $1,773 Up 12% (operationally) | U.S. | $ | 1,086 | $ | 948 | 14 | QTD and YTD growth primarily driven by continued market expansion in the U.S., as well as strong demand with continuing uptake in patient diagnosis across international markets and improved access in certain international markets. YTD growth was partially offset by net price erosion in the U.S. as a result of new payer contracts. | |||||||||||||||||||||||||||||||||||||||||
| Int’l. | 687 | 643 | 7 | 9 | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 1,773 | $ | 1,591 | 11 | 12 | ||||||||||||||||||||||||||||||||||||||||||||
| YTD | $5,136 Up 8% (operationally) | U.S. | $ | 3,061 | $ | 2,924 | 5 | |||||||||||||||||||||||||||||||||||||||||||
| Int’l. | 2,076 | 1,767 | 17 | 13 | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 5,136 | $ | 4,692 | 9 | 8 | ||||||||||||||||||||||||||||||||||||||||||||
| Prevnar family | QTD | $1,564 Down 10% (operationally) | U.S. | $ | 1,026 | $ | 1,155 | (11) | QTD decline primarily driven by: •lower vaccination rates in the adult and pediatric indications, as well as market share erosion for the adult indication, both in the U.S.; and •lower demand in the pediatric indication in certain international markets. YTD decline primarily driven by: •lower vaccination rates in the adult and pediatric indications, as well as market share erosion for the adult indication, both in the U.S., partially offset by: •favorable buying patterns in both the pediatric and adult indications, primarily in the U.S.; •higher net price in the pediatric indication in the U.S.; and •higher market share and demand earlier in the year across certain international markets in both the pediatric and adult indications, despite lower demand in the current quarter. | |||||||||||||||||||||||||||||||||||||||||
| Int’l. | 538 | 587 | (8) | (9) | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 1,564 | $ | 1,742 | (10) | (10) | ||||||||||||||||||||||||||||||||||||||||||||
| YTD | $4,591 Down 5% (operationally) | U.S. | $ | 2,827 | $ | 3,185 | (11) | |||||||||||||||||||||||||||||||||||||||||||
| Int’l. | 1,764 | 1,601 | 10 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 4,591 | $ | 4,786 | (4) | (5) | ||||||||||||||||||||||||||||||||||||||||||||
| Ibrance | QTD | $1,082 Up 3% (operationally) | U.S. | $ | 761 | $ | 670 | 14 | QTD growth primarily driven by higher demand mostly in the U.S. and certain developed markets, favorable buying patterns and higher net price, both in the U.S., partially offset by the non-recurrence of a favorable rebate accrual adjustment in the prior year for certain international markets related to prior periods and competitive pressure in certain emerging markets. YTD growth primarily driven by higher demand in the U.S. and certain developed markets, partially offset by the non-recurrence of a favorable rebate accrual adjustment in the prior year for certain international markets related to prior periods, lower net price in the U.S., as well as unfavorable buying patterns and competitive pressure in certain emerging markets. | |||||||||||||||||||||||||||||||||||||||||
| Int’l. | 321 | 387 | (17) | (16) | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 1,082 | $ | 1,057 | 2 | 3 | ||||||||||||||||||||||||||||||||||||||||||||
| YTD | $3,148 Up 1% (operationally) | U.S. | $ | 2,100 | $ | 2,024 | 4 | |||||||||||||||||||||||||||||||||||||||||||
| Int’l. | 1,048 | 1,058 | (1) | (5) | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 3,148 | $ | 3,083 | 2 | 1 | ||||||||||||||||||||||||||||||||||||||||||||
| Padcev | QTD | $720 Up 55% (operationally) | U.S. | $ | 696 | $ | 449 | 55 | QTD and YTD growth primarily driven by increased market share in first-line locally advanced or metastatic urothelial cancer (la/mUC), as well as launch uptake in the cisplatin-ineligible indication for muscle-invasive bladder cancer. YTD growth was partially offset by a one-time favorable impact associated with transition to a wholesaler distribution model in the U.S. in the prior year. | |||||||||||||||||||||||||||||||||||||||||
| Int’l. | 24 | 16 | 53 | 49 | ||||||||||||||||||||||||||||||||||||||||||||||
| Worldwide | $ | 720 | $ | 464 | 55 | 55 | ||||||||||||||||||||||||||||||||||||||||||||
| YTD | $1,979 Up 38% (operationally) | U.S. | $ | 1,929 | ||||||||||||||||||||||||||||||||||||||||||||||
Next expected filings
- ~2027-02-25 10-K expected by 2027-03-27 (in 95 days)
- ~2027-05-04 10-Q expected by 2027-05-07 (in 163 days)
- ~2027-08-03 10-Q expected by 2027-08-06 (in 254 days)
- ~2027-11-02 10-Q expected by 2027-11-05 (in 345 days)
Predicted from historical filing cadence; not an SEC commitment.
Recent SEC filings
- 2026-11-03 8-K Earnings Release; Financial Statements and Exhibits
- 2026-11-03 10-Q Quarterly Report
- 2026-11-03 8-K Officer/Director Change; Financial Statements and Exhibits
- 2026-08-04 8-K Earnings Release; Financial Statements and Exhibits
- 2026-08-04 10-Q Quarterly Report
- 2026-06-18 8-K Officer/Director Change; Financial Statements and Exhibits
- 2026-05-05 10-Q Quarterly Report
- 2026-05-05 8-K Earnings Release; Financial Statements and Exhibits
- 2026-05-05 S-8 Employee Benefit Plan Registration
- 2026-02-26 10-K Annual Report
- 2026-02-03 8-K Earnings Release; Financial Statements and Exhibits
- 2025-11-21 8-K Other Events; Financial Statements and Exhibits
- 2025-11-13 8-K Other Events
- 2025-11-04 10-Q Quarterly Report
- 2025-11-04 8-K Earnings Release; Financial Statements and Exhibits